|
gptkbp:instanceOf
|
gptkb:recombinant_human_growth_hormone
gptkb:investigational_drug
gptkb:chemical_compound
|
|
gptkbp:affects
|
gptkb:prolactin
glucose metabolism
cortisol
body composition
insulin-like growth factor 1 (IGF-1)
growth hormone (GH)
|
|
gptkbp:alsoKnownAs
|
gptkb:Ibutamoren
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:bioavailability
|
oral, high
|
|
gptkbp:CASNumber
|
159752-10-0
|
|
gptkbp:clinicalTrialPhase
|
Phase II
|
|
gptkbp:compatibleWith
|
gptkb:SARM
gptkb:anabolic_steroid
controlled substance (US)
|
|
gptkbp:developedBy
|
Reverse Pharmacology
|
|
gptkbp:discoveredBy
|
1990s
|
|
gptkbp:eliminationHalfLife
|
24 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C27H36N4O5S
|
|
gptkbp:KEGGID
|
D10868
|
|
gptkbp:legalStatus
|
investigational
|
|
gptkbp:mechanismOfAction
|
stimulates growth hormone release
ghrelin receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
528.66 g/mol
|
|
gptkbp:not_approved_by
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:PubChem_CID
|
140375
159632
CHEMBL1214128
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
muscle pain
increased appetite
mild edema
transient increase in cortisol
|
|
gptkbp:structure
|
amide group
thiazole ring
benzyl group
nitrile group
|
|
gptkbp:UNII
|
QX8X9C6UFZ
|
|
gptkbp:usedFor
|
potential treatment of growth hormone deficiency
potential treatment of muscle wasting
potential treatment of obesity
potential treatment of osteoporosis
|
|
gptkbp:bfsParent
|
gptkb:557795-19-4
gptkb:193275-84-2
gptkb:151096-09-2
gptkb:170729-80-3
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MK-677
|